Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565646 | 0.87 | POLB (0.54) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1565499 | 0.85 | S1PR1 (0.45) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1566102 | 0.85 | S1PR1 (0.45) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1564751 | 0.85 | S1PR1 (0.60) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1565276 | 0.85 | RAB9A (0.48) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1566012 | 0.84 | NPC1 (0.47) | KDM4EPOLBS1PR1S1PR3NPC1 | |
| SCHEMBL1565503 | 0.84 | F2 (0.51) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1566010 | 0.82 | MAPT (0.44) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1564998 | 0.82 | S1PR1 (0.43) | KDM4EPOLBS1PR1S1PR3FFAR2 | |
| SCHEMBL1565292 | 0.82 | KDM4E (0.45) | KDM4EPOLBS1PR1S1PR3FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | claimed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | claimed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | KDM4E 1464/4885POLB 3388/4885GCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.